In this investigation we correlated platelet Na-H antiport parameters with blood pressure and serum lipids in a sample population of non-insulin-dependent diabetic obese, nondiabetic obese, and nondiabetic nonobese black women. Parameters of the Na-H antiport were examined in aspirin-treated platelets. These parameters were not altered in resting or in thrombin-stimulated platelets of diabetic patients. The activity index of platelet Na-H antiport after thrombin stimulation was positively correlated with the blood pressure (systolic blood pressure, r=0.5320 and p=0.0001; diastolic blood pressure, r=0-5123 and p=0.0017). Lower high density lipoprotein cholesterol levels were associated with an alkaline shift in the cytosolic pH set point for activation of the Na-H antiport. Highly significant correlations were also observed between the total cholesterol/high density lipoprotein cholesterol ratio and the cytosolic pH set point for activation of the Na-H antiport These correlations were independent of diabetes or the body mass index. Together, these observations indicate that parameters of platelet Na-H antiport are altered with an increase in blood pressure and a decrease in serum high density lipoprotein cholesterol.
tween the platelet Na-H antiport and the blood pressure and lipid profiles?
Methods

General Procedures
Diabetic obese, nondiabetic obese, and nondiabetic nonobese black women (12 subjects in each group) were recruited from the Diabetic Ginic and the staff of the University of Medicine and Dentistry of New Jersey. All diabetic patients had a body mass index (BMI) >29 kg/m 2 . Nondiabetic obese subjects were matched by BMI and age with their diabetic obese counterparts. Since the present study focused on platelet Na-H antiport in NIDDM and obesity without complicating hypertension, subjects with marked hypertension (i.e., blood pressure > 150/100 mmHg) or those receiving antihypertensive treatment were excluded from the study. Subjects exhibited no metabolic diseases (except NIDDM) or abnormal renal function (creatinine >1.5 mg% or proteinuria, i.e., urinary albumin >300 mg%) and were taking no medications except oral hypogrycemic agents (four patients) and insulin (six patients). Subjects did not take any nonprescription analgesics with potential effects on platelet function for at least 2 weeks before the study. Diabetic patients did not take their medications on the morning of the study.
Blood was drawn between 8 and 9 AM after an overnight fast. Before blood drawing, blood pressure measurements were obtained with a mercury sphygmomanometer after a resting period of 5-10 minutes (subject was sitting in a comfortable position). The average of three blood pressure measurements, taken at 2-minute intervals, was used. Diastolic blood pressure was determined as the fifth Korotkoff sound. After blood pressure measurements, 50 ml blood was drawn into acid dextrose buffer (20/1; vol/vol) consisting of (in mM) sodium citrate 14, citric acid 11.8, and dextrose 18 (final pH 6.5). An additional 10 ml blood was drawn for serum lipid profile, fasting glucose, insulin, and creatinine. Informed consent, approved by the institutional review board, was obtained from all subjects.
Platelet Preparations
In preliminary experiments five of 11 preparations from diabetic obese patients demonstrated gross aggregation during the process of platelet isolation. Treatment of the preparations with aspirin resolved the tendency for aggregation. For this reason, all subsequent experiments were performed using aspirintreated platelets.
Platelet-rich plasma was obtained by centrifugation at 200 g for 10 minutes at room temperature. This fraction was centrifuged at l,000g for 10 minutes, and cells were washed three times (by centrifugation at l,000g for 10 minutes) in buffer of the following composition (in mM): NaCl 140, KC1 5, glucose 10, EGTA 0.2, HEPES 10, and aspirin 0.1. Fatty acid-free bovine serum albumin (BSA) (0.1%) was added to the third washing.
Platelets were loaded with BCECF-AM (Molecular Probes, Eugene, Ore.) by their incubation with the fluorescent probe for 60 minutes at 37°C in HEPES buffered solution (HBS) comprising (in mM): N a d 140, KC1 5, M g d 2 1 , CaCl 2 1, glucose 10, HEPES 10 (pH 7.4).
Measurements of the Na-H Antiport Parameters
Aliquots of 100 u\ of (1-3 xlO 6 ) dye-loaded platelets were rapidly centrifuged to remove the extracellular dye. Platelets, suspended in 80 ^tl dye-free HBS, were rapidly injected into 3 ml HBS plus 0.1% BSA (pH=7.4) in which sodium propionate equimolarily replaced NaCl with or without 0.1 National Institutes of Health units/ml human thrombin (No. 9135, Sigma Chemical Co., St. Louis, Mo.). Changes in the cytosolic pH (pH) were followed up to 80 seconds. Basal pHj and cellular buffering power were measured in nonacidified platelets. The latter measurement used the ammonium chloride method. 18 Measurements of the pH, were performed (at 37°C) in SPEX Fluorolog II spectrometer (model CM-3). Excitation and emission wavelengths were set at 440/503 and 530 nm, respectively.
Other Measurements
Serum glucose was determined by the glucose oxidase method. Total cholesterol (TC), triglycerides (TG), and high density lipoprotein (HDL) cholesterol were determined by colorimetric methods using reagent kits supplied by Sigma Chemical Co. Low density lipoprotein (LDL) cholesterol was calculated as follows: total cholesterol minus HDL minus very low density lipoprotein (VLDL). VLDL was computed as 20% of TG. Plasma insulin was determined by a double antibody radioimmunoassay (Pharmacia Diagnostics, Fairfield, NJ.).
Data Analysis
The initial rates of recovery from cellular acidification (with or without thrombin) were obtained from iterative curve fitting of the data as described previous- ly. 19 The apparent set point (Xj), expressed in cytosolic H + concentration ([H + ]|), and the activity index (Zj) of the Na-H antiport were obtained by linear regressions describing the relation between the initial rate of pH, recovery (y axis) as a function of the initial [H + ], from which the recovery proceeded (x axis). This approach is illustrated in Figure 1 . Thex-axis intercept of the linear regression is the Xj, whereas the slope is the Zj for the Na-H antiport within the tested range of [H + ],. An alkaline shift in the Xj is expressed by a shift to the left in the x-axis intercept, whereas an increase in the Zj is described by an increment in the slope of the regression line. A usual response to thrombin and other agonists that activate the Na-H antiport is an alkaline shift in the Xj, increased Z,, or both (for further details, see References 20 and 21). The AZ, expresses the increase in the activity index of the Na-H antiport after thrombin treatment, and it represents the extent of Na-H antiport stimulation by thrombin within the range of [H + ]i tested. Statistical evaluation used one-way analysis of variance (followed, if necessary, by the Duncan multiple range test) and correlation analyses. All computations were performed with an IBM-compatible personal computer (SAS, REG, and GLM programs, SAS Institute, Cary, N.C.). Because of technical problems, not all platelet parameters were examined in all subjects. Unless otherwise indicated, each group presented in the tables and figures consists of 12 subjects. Data in tables are presented as mean±SEM.
Results Both the diabetic obese and nondiabetic obese groups demonstrated higher blood pressure levels than the nondiabetic nonobese group. The highest blood pressure in the diabetic obese group was 146/97 and that in the nondiabetic obese group was 150/92 mm Hg. Although the systolic blood pressure was higher in the nondiabetic obese than in the diabetic obese group, the difference was not statistically significant (Table 1) . There were also several differences among the groups in the serum lipid profile and glucose and insulin levels ( Table 2) . TG and VLDL levels were significantly higher in diabetic obese and nondiabetic obese groups compared with the nondiabetic nonobese group. However, no significant differences in HDL or TC were observed among the groups.
No statistically significant differences were observed among the three groups in pH,, cellular buffering power, and Na-H antiport parameters before or after treatment with thrombin (Table 3 ). However, highly significant correlations were observed between the blood pressure and the AZ,, i.e., the increment in the activity index of the Na-H antiport after thrombin stimulation (Figure 2 ). These correlations maintained their significance after exclusion of the diabetic obese subjects, that is, the relation between the AZj and the blood pressure held in the nondiabetic subjects. It is noteworthy that platelets from several subjects (three diabetic obese, one nondiabetic obese, and one nondiabetic nonobese) demonstrated a paradoxical decline (i.e., a negative value in the AZ,) after treatment with thrombin. The underlying reason for this tendency was not clear. The significant correlation between blood pressure and the Zj primarily resulted from the thrombin effect since the Zi in platelets not treated with thrombin was not correlated with the blood pressure. The correlation between the Z; and blood pressure in thrombin-treated platelets were as follows for the entire population: systolic, r=0.5023 and p=0.0021; diastolic, r=0.4610 and/?=0.0053; mean pressure, r=0.5144 and p=0.0016. For the nondiabetic subjects, the correlation parameters were systolic, r=0.5761 and/?=0.0040; diastolic, r=0.5104 and/?=0.0128; mean arterial pressure, r=0.5509and/?=0.0060.
A significant negative correlation was observed between the Xi and HDL, and the significance was further increased when the Xj was correlated with the TC/HDL ratio ( Figure 3) . The significance of these correlations was maintained when the diabetic obese subjects were excluded. Platelets from one diabetic obese patient showed a negative Xjj this implies that the Na-H in these platelets was active throughout the [H + ], scale (see Figure 1) . Exclusion of this patient did not substantially alter the overall significance of the correlations. Discussion A major, not yet fully resolved, problem that can undermine studies of platelets of patients with NIDDM and dyslipidemias is the increased tendency of these platelets to aggregate during the process of their isolation from other blood elements. This problem is of particular relevance to the examination of the platelet Na-H antiport since this transport system is stimulated during platelet activation. Therefore, altered parameters of the Na-H antiport in platelets from some subjects may not necessarily indicate a different behavior of this system in vivo. Rather, these alterations could reflect platelet activation during platelet isolation. Ishii et al 22 showed that the cytosolic free calcium (Ca^ response to agonists was increased only in platelets of patients with NIDDM who demonstrated enhanced platelet aggregation. Our experiments showed that non-aspirin-treated platelets from five of 11 patients with NIDDM exhibited gross aggregation during their isolation. The remaining six samples showed higher basal Ca) compared with aspirin-treated platelets (not shown). Together these findings suggest the following possibilities: 1) some activation during isolation occurs even in platelets that do not show gross aggregation, 2) the cyclooxygenase pathway is hyperactive in platelets of patients with NIDDM, or 3) both of these processes are present. These observations and a recent confirmation of in- BpH, basal pH; BPW, cellular buffering power (mniol • liter ' • pH '); X;, cytosolic set point for the activation of the Na-H antiport (micromoles H + ); Z(, the activity index of the Na-H antiport (pH units/sec • ^M H + ); X|(t), X) after thrombin stimulation; Z,(t), Zj after thrombin stimulation; Norm, nondiabetic nonobese group; Obese, nondiabetic obese group; NIDDM, diabetic obese group. creased thromboxane turnover rate in platelets from NIDDM patients 23 underlie our decision to examine the Na-H antiport in aspirin-treated platelets, namely, un- der conditions in which the cyclooxygenase pathway is inhibited. This metabolic pathway leads to the formation of unstable prostaglandin endoperoxides that are converted to thromboxane A 2 . The action of the latter compound promotes irreversible platelet aggregation through activation of phospholipase C. Thus, the tradeoff for maintaining the stability of the platelet preparation is that the results reflect observations in platelets with an inhibited cyclooxygenase pathway. The major finding of the present work is that in themselves, NIDDM and obesity are not expressed in altered platelet Na-H antiport parameters. However, even within the normotensive range, the blood pressure level and the serum lipid profile are associated with changes in the behavior of the Na-H antiport. Since elevated blood pressure and dyslipidemia frequently complicate NIDDM, it is very likely that altered activity of platelet Na-H antiport is commonly observed in diabetic and obese subjects with marked hypertension. Recently we found no significant alterations in Na-H antiport parameters of hypertensive compared with normotensive black women. 17 In that study the behavior of the Na-H antiport was examined only in resting platelets. Thus, both studies agree in that the Zj of unstimulated platelets does not correlate with the blood pressure in black women. However, blood pressurerelated variations become apparent when platelet Na-H antiport is stimulated by thrombin. The positive correlation between the AZ, and blood pressure may therefore reflect increased platelet sensitivity to thrombin and a higher thrombin-evoked Cai response associated with a higher blood pressure. Our recent findings (unpublished data, Zentay et al) indicates that the Z( was positively correlated with the thrombin-evoked rise in the Caj.
In a recent study Livne et al 14 have shown that resting platelets of presumably white hypertensive men exhibited an alkaline shift in the X, and increased activity of the Na-H antiport. Since gender and racial extraction influence parameters of platelet Na-H antiport, 17 it is difficult to compare the two studies. Moreover, the serum lipid profile was not examined by Livne and coworkers, and as shown in the present work, it may influence the X^. This fact may turn out to be an important issue since dyslipidemia complicates both essential hypertension and NIDDM.
Dyslipidemia is frequently associated with altered platelet activity.
-
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- 12 It is worth noting that HDL, particularly apolipoprotein E-rich HDL, inhibits platelet aggregation 24 -28 and diminishes the risk for coronary heart disease and atherosclerosis. 29 -30 This effect of HDL on platelets may relate to its capacity to release cholesterol from the plasma membrane 24 since increased serum cholesterol or platelet cholesterol con- tent is associated with increased platelet sensitivity to aggregating agents. 91112^1 In this context, our finding of a negative correlation between the Xj (expressed in pH units) and HDL and a positive correlation between the Xj (expressed in pH units) and the TC/HDL ratio is of interest (insets to Figure 3) . The latter ratio is considered an index of coronary heart disease risk, and its significant correlation with the X| of platelet Na-H antiport probably reflects such a risk expressed in platelet hyperactrvity.
We recently proposed that an alkaline shift in the Xj and increased Zj represent a homeostatic response that marks increased platelet activity. 20 - 21 Platelet hyperactrvity is frequently associated with a rise in Ca<; the resulting increase in metabolic activity and the stimulation of the plasma membrane Ca-ATPase (an exchanger of cellular calcium for extracellular proton) would promote cellular acidification. Coupled with an increase in the Z,, an alkaline shift in the X; could therefore serve to attenuate this tendency for cytosolic acidification. Thus, an alkaline shift in the Xj may be the lasting imprint of elevated Caj and platelet hyperactrvity. A number of investigations have shown a positive correlation between platelet Caj and blood pressure. 32 - 34 A rise in platelet Caj is also observed when serum TC is increased, HDL is diminished, or when both perturbations are concurrently present. 24 Moreover, such serum lipid abnormalities are frequently observed in both essential hypertension and NTDDM.
Measurements of Na-H antiport parameters in the present investigation were performed in washed platelets suspended in HBS, a medium that does not reflect the elevated plasma glucose and insulin levels in patients with NIDDM or obesity. May et al 35 recently reported that glucose increases platelet aggregation in whole blood. They attributed this effect to glucoseevoked liberation of ADP and other platelet-aggregating agents from erythrocytes. Such a process does not apply to the present work, which was performed in washed platelets free of erythrocytes. Insulin receptors are present on platelets and they can be downregulated in diabetes. 36 " 38 However, a controversy exists concerning whether these receptors are coupled to intracellular signals. 39 
"
41 It is still possible, nonetheless, that hyperinsulinemia and hyperglycemia do influence platelet function in vivo and that their effects would last in vitro even in the absence of elevated levels of insulin and glucose in the experimental medium.
In conclusion, in a sample population of nondiabetic nonobese, nondiabetic obese, and diabetic obese black women, parameters of the Na-H antiport in aspirintreated platelets were significantly correlated with blood pressure as well as serum HDL and the TC/HDL ratio.
